Tamara Elias, MD
Dr. Tamara Elias has been avidly involved with healthcare for over 20 years across a wide spectrum of diverse experiences, beginning with medical school, extending into surgical residency, followed by healthcare strategic consulting, private equity investing, corporate strategy and business development, product innovation and P&L, and global partnerships, inclusive of board member positions.
Currently SVP, Strategic Initiatives and Business Incubation at Nuance Communications, a Microsoft Company, she orchestrates complex’s processes and initiatives to understand how these two company’s unique assets can be used to advance workflows and improve diagnoses across the healthcare ecosystem. At Merck, she was VP, Head of Global Partnerships & Innovation, realizing “around the pill” innovations for their stakeholders. At Aetna, she was VP, Clinical Product Development owning a $20M P&L, and focused on optimizing and rationalizing the existing clinical product portfolio for all lines of business as well as aligning future product and service design with the Aetna digital roadmap and customer needs within each business segment. At Becton Dickinson, Dr. Elias was VP, Corporate Strategy and Business Development for the $8B revenue Medical Segment. In this role, she engineered the creation of the Digital Health Business Unit – from designing the organization to securing funding to hiring the team and getting the approval of the first concept in digital diabetes. As a member of the Leadership Team she advanced the overall strategic direction and growth for the medical segment, including the $24B acquisition of Bard.
As a Partner with Essex Woodlands, Dr. Elias co-led the healthcare services and healthcare IT Growth Equity practice and managed the medical device growth equity portfolio and practice. She served on the Boards of Millennium Pharmacy Systems (sold to Pharmerica), BreatheAmerica, and Influence Health (sold to Healthgrades). She also served on the board of ATS Medical, a leading developer and manufacturer of products and services focused on cardiac surgery, which was sold to Medtronic.
Prior to Essex Woodlands, Dr. Elias was a senior engagement manager at McKinsey, where she advised pharmaceutical, diagnostic and device companies in product commercialization and M&A.
In addition to being a Director with BehaVR, Dr. Elias currently serves on the Board of Directors of Avinger (NASDAQ: AVGR), a public medtech company in the PVD space, as Chairman of the Nominating/Governance Committee and a Member of the Audit and Comp Committees, as well as on the board of REVA Medical LLC, also in the PVD space.
Dr. Elias holds a BA in both Biology and Anthropology from Yale University, obtained her MD from The Johns Hopkins School of Medicine, and pursued a general surgery residency at Massachusetts General Hospital.